Heartflow, Inc. · NASDAQ:HTFL
Heartflow — SPAC Merger (October 2021)
30 slides from Heartflow's SPAC merger presentation, October 2021
Slide 1: Investor Presentation October 2021
Investor Presentation October 2021
Slide 2: Disclaimer
Disclaimer Disclaimer This presentation is for information purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between HeartFlow Holding, Inc. (“HeartFlow”) and Longview Acquisition Corp. II (“Longvi
Slide 3: Disclaimer (continued)
Disclaimer (continued) Industry and Market Data In this Presentation, Longview and HeartFlow rely on and refer to certain information and statistics obtained from third-party sources which they believe to be reliable. Neither Longview nor HeartFlow has independently verified the accuracy or complete
Slide 4: Transaction Overview
Transaction Overview HeartFlow is preparing to go public through a SPAC Merger with Longview Acquisition Corp. II • HeartFlow Holding, Inc. (“HeartFlow”) is revolutionizing precision “heart care” with non-invasive personalized cardiac tests and enterprise software suite solutions, which provide unpr
Slide 5: Transaction Overview
Transaction Overview ($ in mm, except per share values) Key Highlights Sources Uses • HeartFlow will be appropriately capitalized with ~$400mm of Equity to HeartFlow Stockholders $2,150.0 Equity to HeartFlow Stockholders $2,150.0 net cash (assuming no redemptions) post-closing Longview Cash Held in
Slide 6: Slide 6
Slide 7: Cardiovascular Disease Costs Will Exceed $1 Trillion by 2035
Addressing the Number One Cause of Death and Largest Component of Chronic Health Spend More than twice as many 1 out of every 3 1 billion people in the world at deaths as the 2nd most deaths moderate to high risk today common cause (cancer) Center for Health Metrics and Evaluation Cardiovascular Dis
Slide 8: The Status Quo Heart Disease Care Pathway Dominated by Echo & Nuclear Stress Testing
The “Status Quo” Heart Disease Care Pathway Dominated by Echo & Nuclear Stress Testing is Suboptimal Non-invasive Testing Invasive Testing Risk Assessment 10M non-invasive tests in 2M+ catheterizations in the US alone every year the US alone every year3 Multiple possible Multiple layers starting poi
Slide 9: Driven by a Mission to Improve Cardiovascular Care
12 Driven by a Mission to Improve Cardiovascular Care for Patients, Physicians, Providers and Payers 9
Slide 10: The HeartFlow Heart Disease Pathway Enhances Patient Experience and Delivers Cost Savings
The HeartFlow Heart Disease Pathway Enhances the Patient Experience, Improves Outcomes and Delivers Cost Savings Anatomy and physiology in one test HIGHER ACCURACY1 83% REDUCTION in unnecessary invasive angiograms2 IDENTIFY DISEASE <1% LIKELIHOOD of missing disease3 $2.7B annual cost-savings deliver
Slide 11: Over a Decade Solving Technical, Business and Regulatory Challenges
HeartFlow Has Spent Over a Decade Solving the Technical, Business and Regulatory Challenges Necessary to Unlock All Barriers to Adoption 2010 2014 2017 2019 2021 HeartFlow founded US FDA De Novo Clearance Commercial coverage began ESC Guidelines ACC/AHA chest pain CMS engagement initiated Majority o
Slide 12: Delivering Precise, Personalized and Enhanced Care Decisions for Patients
Delivering Precise, Personalized and Enhanced Care Decisions for Patients Monitor Assess • Ongoing patient monitoring coupled with • The historical path to diagnosing CAD is patient history ensures physicians and unclear, unreliable, insufficient and patients will remain vigilant about CAD ineffecti
Slide 13: Revolutionary Precision Heart Care Technology
HeartFlow Developed and Introduced a Revolutionary Precision “Heart Care” Technology that Disrupts the Status Quo HeartFlow’s product suite leverages and builds upon a foundational technology platform Precision Diagnostics Optimization of Therapy Informed Clinical Coronary Computed Decision Tomograp
Slide 14: AI-enabled, Cloud-based Enterprise Software Suite
Empowering Physicians with an AI-enabled, Cloud-based Enterprise Software Suite • AI-powered modeling of all coronary arteries ADVANCED TECH • Highest diagnostic accuracy driven by big data analytics • Compliant cloud computing to protect sensitive data • Secure bi-directional data transmission to /
Slide 15: AGE: 60 68. SEX: SEX: MALE
AGE:6068. SEX: AGE: SEX: MALE MALE HISTORY:SYMPTOMATIC, HISTORY: ASYMPTOMATIC, FAMILY FAMILY HISTORY HISTORY OF OF HEART HEART DISEASE DISEASE *Currentlyinindevelopment developmentand andnot notavailable availablefor forclinical clinicaluse. use. 15 *Currently 15
Slide 16: Providing Significant Clinical Evidence
Providing Significant Clinical Evidence Since inception, HeartFlow has been committed to producing comprehensive clinical evidence to substantiate the diagnostic accuracy, safety, efficacy, cost-effectiveness, and utility of its product portfolio ROBUST EVIDENCE ≫ 16 company-sponsored clinical trial
Slide 17: Leveraging a Strong Intellectual Property Portfolio
Leveraging a Strong Intellectual Property Portfolio HeartFlow’s differentiated IP portfolio provides a powerful competitive advantage, while a significant imaging database fuels an AI-based technology roadmap to drive incremental automated product enhancements 400+ Issued patents worldwide 15 Millio
Slide 18: Unlocked Barriers Driving Adoption by Societies, Providers and Payers
Unlocked Barriers Driving Adoption by Key Cardiology Societies, Providers and Payers The CTA + HeartFlow pathway is trusted by leading US hospitals and has been prioritized by US payers 80% of the Top 50 Heart Hospitals1 96% in the US Have Adopted HeartFlow US commercial lives covered System-Wide Ad
Slide 19: Predictable and Attractive SaaS Model
Predictable and Attractive SaaS Model Combining Fee-per-analysis and Base Subscription Layers Historically successful business model incorporates hybrid approach of fee-per-analysis (consumption based at a fixed per test rate) and enterprise software suite subscription (annual bundled contract) Reve
Slide 20: Robust Software Pipeline to Fuel a Significant TAM
Augmented by a Robust Software Pipeline to Fuel a Significant TAM HeartFlow is developing a comprehensive, integrated cloud-based heart care technology product suite to help physicians make more optimal cardiovascular care decisions Plaque Myocardial FFRCT Planner PreRead Analysis Insights Anatomy a
Slide 21: Robust Software Pipeline to Fuel a Significant TAM
Augmented by a Robust Software Pipeline to Fuel a Significant TAM From a fraction of a fraction to a majority of a majority • Over the coming 15 years, we envision HeartFlow moving from a small minority of coronary CTA scans to being attached to the vast majority • Additionally, over the same period
Slide 22: Robust Software Pipeline to Fuel a Significant TAM
Augmented by a Robust Software Pipeline to Fuel a Significant TAM HeartFlow has a clear projected development path to grow TAM from $10B to $50B+ Illustrative HeartFlow TAM Evolution1 Today Near Term Medium Term Long Term Symptomatic HeartFlow Risk Assessment $24.0B Asymptomatic / Preventative Acces
Slide 23: Fueling a Compelling High Growth Outlook
Fueling a Compelling High Growth Outlook Management believes that HeartFlow’s financial forecast is supported by a highly predictable and leverageable business model with a robust commercial pipeline, favorable industry tailwinds, and no customer churn Key Growth Drivers Near-Term Mid- Term ● Antici
Slide 24: Near-Term Growth Drivers
Fueling a Compelling High Growth Outlook: Near-Term Growth Drivers Anticipated industry tailwinds to accelerate the shift from stress testing to the CTA-FFRCT pathway 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Chest Pain A Report of the American College of C
Slide 25: Near-Term Growth Drivers: US Sales Expansion
Fueling a Compelling High Growth Outlook: Near-Term Growth Drivers Expanded US sales footprint to capitalize on industry tailwinds and new customer offerings US Sales Expansion HeartFlow Unlimited + • A standardized workflow where all coronary CTAs are sent to HeartFlow (to facilitate • Enhanced sal
Slide 26: Fueling a Compelling High Growth Outlook
Fueling a Compelling High Growth Outlook Management believes that HeartFlow’s financial forecast is supported by a highly predictable and leverageable business model with a robust commercial pipeline, favorable industry tailwinds, and no customer churn 2021-2025 Plan R $600 5E CAG $525 1 E-’2 % ’2 R
Slide 27: Led by a Strong Team
Led by a Strong Team Leadership Team Senior Team John Stevens, M.D.* William C. Weldon* Heather Brown Tim Fonte President & CEO, Co-founder Board Chair SVP, Market Access & SVP, Customer Success Heartport, Amp Resources, Stanford Former Chairman & CEO, J&J Reimbursement Stanford University, Cameron
Slide 28: Fortified by Experienced Investment Partners
Fortified by Experienced Investment Partners Existing HeartFlow Investor Base 28
Slide 29: Enabling Access to Optimized Care for All Patient Populations
Enabling Access to Optimized Care for All Patient Populations Investors’ collective investment and partnership with HeartFlow will achieve meaningful societal goals HeartFlow’s Technical Strengths Societal & Commercial Opportunity Disruptive, Best-in-class Improve Diagnostic Accuracy Robust Intellec
Slide 30: Thank You!
Thank You! O HeartFlow’